Covered recipient · General Payments record
HYOLIM SONG
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Adult Health
General Payments · PY2023–2024
$762.26
- Reported across 18 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $601.77 | 14 |
| Education | $83.99 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $229.05 | 3 |
| Genentech, Inc. | $145.53 | 2 |
| ABBVIE INC. | $87.39 | 1 |
| Genentech USA, Inc. | $78.63 | 3 |
| Lilly USA, LLC | $42.04 | 2 |
| AVEO Pharmaceuticals, Inc. | $33.03 | 1 |
| Alexion Pharmaceuticals, Inc. | $26.74 | 1 |
| Celgene Corporation | $21.90 | 1 |
| E.R. Squibb & Sons, L.L.C. | $21.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $87.39 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108231245 | CMS |
| Alexion Pharmaceuticals, Inc. | $26.74 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1094034168 | CMS |
| Aveo Pharmaceuticals, Inc. | $33.03 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143493095 | CMS |
| Celgene Corporation | $21.90 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101123724 | CMS |
| E.R. Squibb & Sons, L.L.C. | $21.45 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101380606 | CMS |
| Genentech USA, Inc. | $31.04 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133161511 | CMS |
| Genentech USA, Inc. | $23.59 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133161507 | CMS |
| Genentech USA, Inc. | $24.00 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133161515 | CMS |
| Genentech, Inc. | $46.67 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133161499 | CMS |
| Genentech, Inc. | $98.86 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133161503 | CMS |
| Incyte Corporation | $18.11 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141273646 | CMS |
| Incyte Corporation | $126.95 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141267303 | CMS |
| Incyte Corporation | $83.99 | 05/20/2024 | Education | Undisputed | 01/23/2026 | 1141267349 | CMS |
| Lilly USA, LLC | $21.02 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135682197 | CMS |
| Lilly USA, LLC | $21.02 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135681511 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.